Threshold Pharmaceuticals, Inc. (NASDAQ:MTEM) issued its quarterly earnings data on Monday, July 31st. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.77) by $0.99, reports. The business had revenue of $3 million during the quarter.
Threshold Pharmaceuticals (MTEM) traded down 1.51% during midday trading on Friday, hitting $5.88. The stock had a trading volume of 31,581 shares. Threshold Pharmaceuticals has a 1-year low of $3.85 and a 1-year high of $16.28. The stock’s 50-day moving average is $5.29 and its 200-day moving average is $5.71. The stock’s market capitalization is $38.27 million.
Several equities analysts recently issued reports on the company. Ladenburg Thalmann Financial Services assumed coverage on Threshold Pharmaceuticals in a research report on Thursday, August 3rd. They issued a “buy” rating and a $10.00 price objective for the company. Stifel Nicolaus reaffirmed a “hold” rating and set a $0.40 price target on shares of Threshold Pharmaceuticals in a research report on Thursday, August 3rd. Finally, ValuEngine raised Threshold Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 3rd.
In other news, Director Jeffrey W. Bird acquired 510,703 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was purchased at an average price of $0.57 per share, for a total transaction of $291,100.71. Following the completion of the acquisition, the director now directly owns 919 shares in the company, valued at approximately $523.83. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 12.97% of the company’s stock.
Threshold Pharmaceuticals Company Profile
Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.